

# **POST-TRAUMATIC STRESS DISORDER**

## **Comorbidity and Treatment**

**Kathleen T. Brady, M.D., Ph.D.**

**R. Bruce Lydiard, M.D., Ph.D.**

**Medical University of South Carolina  
Charleston, SC**

# Pre-Lecture Exam

## Question 1

True or False:

1. The prevalence of PTSD is higher in women than men.

## Question 2

True or False:

2. Combat-related PTSD is not responsive to treatment.

## Question 3

True or False:

- Propranolol is an effective treatment for PTSD.

## Question 4

1. Pharmacological agents with proven efficacy in PTSD include all but which of the following:
  - A. SSRI's
  - B. TCA's
  - C. MAOI's
  - D. Benzodiazepines
  - E. Anticonvulsants

## Question 5

1. The psychosocial PTSD treatment with the strongest evidence for efficacy is:
  - A. EDMR
  - B. CBT
  - C. Breathing relaxation
  - D. Exposure
  - E. Thought-stopping

# Post-Traumatic Stress Disorder (PTSD)

---

Lifetime prevalence in community of 1% to 14%

One of the least well-studied anxiety disorders

Combat-related PTSD is best studied

PTSD is associated with sexual abuse, physical assault, torture, accidental trauma, natural or man-made disasters, diagnosis of threatening illness

# **POST-TRAUMATIC STRESS DISORDER**

**A characteristic set of symptoms following  
exposure to extreme traumatic stress**

- 5. experience, witness, or confronted with  
actual or threatened death or injury**
- 6. Response involves intense fear,  
helplessness, or horror**

**Duration more than one month**

**Significant functional impairment**



# **POST-TRAUMATIC STRESS DISORDER**

**Experiencing symptoms (1 necessary)**

- 5. intrusive recollections**
- 6. recurrent dreams**
- 7. flashbacks**
- 8. psychological distress with reminders**
- 9. physiologic reactivity with reminders**

# POST-TRAUMATIC STRESS DISORDER

## Avoidance symptoms (3 necessary)

5. avoid thoughts/feelings/conversations
6. avoid activities, places, people
7. inability to remember
8. diminished interest
9. feelings of detachment
10. restricted affect
11. foreshortened future

# POST-TRAUMATIC STRESS DISORDER

## Arousal symptoms (2 necessary)

5. sleep difficulty
6. irritability
7. concentration
8. hypervigilance
9. exaggerated startle

*PTSD*

# DSM-IV Criteria

---

**Exposure to traumatic event with**

**5. Actual or threatened death or serious injury**

**and**

**5. Response involving intense fear, helplessness, or horror**

## *PTSD*

# **DSM-IV Criteria (cont.)**

---

- 5. Re-experiencing the traumatic event**
- 6. Persistent avoidance of stimuli associated with event**
- 7. Numbing of general responsiveness**
- 8. Symptoms of increased arousal**
- 9. At least 1 month's duration (otherwise can diagnose Acute Stress Disorder)**
- 10. Significant distress or impairment in social, occupational, or other functioning**

*PTSD*

# Associated Features

---

5. Alcohol/drug problems
6. Aggression/violence
7. Suicidal ideation, intent, attempts
8. Dissociation
9. Distancing
10. Problems at work
11. Marital problems
12. Homelessness

# *PTSD*

## **Sleep Disturbances**

---

### **Subjective**

- 5. Trauma-related nightmares**
- 6. Insomnia/non-restorative sleep**

### **Objective (EEG findings)**

- 5. Increased REM density/impaired REM sleep maintenance**
- 6. Increased motor activity**

*PTSD*

# Clinical Implications of Sleep Disturbances

---

5. Irritability
6. Vigilance
7. Impaired concentration
8. Increased risk for subsequent mood and anxiety disorders



# Overview of PTSD

---

- 5. Epidemiology**
- 6. Diagnosis**
- 7. Psychiatric Comorbidity**
- 8. Treatment**

# Lifetime Prevalence of DSM-III-R Major Psychiatric Disorders NCS Data

---


	%
<b>Mood Disorders</b>	
Major depressive episode	17.1
Dysthymia	6.4
Manic episode	1.6
<b>Anxiety Disorders</b>	
Social phobia	13.3
Simple phobia	11.3
<b>PTSD</b>	<b>7.8</b>
Agoraphobia without panic	5.3
GAD	5.1
Panic disorder	3.5
<b>Substance Use Disorders</b>	
Alcohol abuse/dependence	23.5
Drug abuse/dependence	11.9

---

Adapted from: Kessler et al. Arch Gen Psychiatry. 1994;51:8–19.  
Kessler et al. Arch Gen Psychiatry. 1995;52:1048–1060.

# Lifetime Prevalence of PTSD

---




Breslau et al. *Arch Gen Psychiatry*. 1991;48:216-222.

Kessler et al. *Arch Gen Psychiatry*. 1995;52:1048-1060.

## PTSD

# Risks of Specific Traumas in the US Population



5. About 30% of people exposed to trauma developed PTSD

Kessler RC et al. *Arch Gen Psychiatry*. 1995;52:1048–1060.

*PTSD*


# Risk Factors for PTSD

---

5. Severity of trauma (ie, threat, duration, injury, loss)
6. Prior trauma
7. Gender
8. Prior mood and/or anxiety disorders
9. Family history of mood or anxiety disorders
10. Education

# PTSD

## Rates Related to Specific Traumas




Kessler RC et al. *Arch Gen Psychiatry*. 1995;52:1048–1060.

# PTSD

## Persistence Over Time


(Untreated Group)



Kessler RC et al. *Arch Gen Psychiatry*. 1995;52:1048–1060.

# PTSD

## Function and Quality of Life In Vietnam Veterans With and Without PTSD



Zatzick DF et al. *Am J Psychiatry*. 1997;154:1690–1695.




# *PTSD*

## Psychiatric Comorbidity

	Lifetime Rates (%)			
	Men		Women	
	PTSD	Non-PTSD	PTSD	Non-PTSD
<b>Depression</b>	48	12	48	19
<b>Mania</b>	12	1	6	1
<b>Panic Disorder</b>	7	2	13	4
<b>Social Phobia</b>	28	11	28	14
<b>GAD</b>	17	3	15	6
<b>Alcohol Abuse/Dependency</b>	52	34	28	13
<b>Substance Abuse/Dependency</b>	34	15	27	8
<b>Any Diagnosis</b>	88	55	79	46


# Comorbidity in PTSD National Comorbidity Study

**MEN**



- 1 Other Diagnoses
- 2 Other Diagnoses
- 3 Other Diagnoses
- No Other Diagnosis

**WOMEN**



- 1 Other Diagnoses
- 2 Other Diagnoses
- 3 Other Diagnoses
- No Other Diagnosis

# COMORBIDITY IN PTSD


**Variability in individual response to stress**

**Heterogeneous disorder**

**Symptom overlap**


## PTSD

# Impact of Comorbid PTSD in Subjects With Other Anxiety Disorders




Warshaw MG et al. *Am J Psychiatry*. 1993;150:1512-1516.

# DIAGNOSTIC SPECTRUMS




PTSD

# Model Sequence of Comorbidity



Davidson JR et al. *Compr Psychiatry*. 1990;31:162–170.  
Mellman TA et al. *Am J Psychiatry*. 1992;149:1568–1574.


# Lifetime History of Suicidal Attempts by Anxiety Disorder



General US population lifetime rates of suicide attempts range from 2.9% to 4.6%.

Kessler RC, *Archives of General Psychiatry*. 1999; Moscicki EK, *Yale Journal of Biology and Medicine*. 1988

# Disability Weights (Rating Scale)





# PTSD: Unmet Medical Need

Few Are Treated

% Lifetime Prevalence

18  
16  
14  
12  
10  
8  
6  
4  
2  
0

■ Untreated  
■ Treated

Depression

Social phobia

PTSD

GA  
D

Panic disorder

OCD

% untreated

50%


90%

75%

80%

50%

30%



# PTSD Treatment Options



## Psychosocial

Exposure therapy  
Cognitive therapy  
Anxiety management  
Desensitization  
EMDR  
Hypnotherapy

## Pharmacologic

SSRIs  
TCAs  
MAOIs  
Mood stabilizers  
Antianxiety agents

EMDR = eye movement desensitization and reprocessing.

*PTSD*

# Treatment Options

---

5. Psychotherapy
6. Pharmacotherapy
7. Multimodal treatment

# **WHO RESPONDS?**

**Gender**

**Trauma**

**Country**

**Comorbidity**

# **WHAT RESPONDS**

**Intrusive, avoidant, numbing,  
hyperarousal Sx**

**Individual symptoms**


**Diagnosis**

**Disability**

**Stress vulnerability**

# PTSD

## Impact of Treatment on Recovery



Kessler RC et al. *Arch Gen Psychiatry*. 1995;52:1048–1060.

## *PTSD*

# Considerations for Psychotherapy

---

- 5. Capacity to tolerate distress with exposure**
- 6. Motivation/preference**
- 7. Ability to participate and follow structure**
- 8. Problems with interpersonal adjustment**

# ANXIETY MANAGEMENT TREATMENT/COMBINATIONS\*

Study	Population	Comparison	Results
Resick et al., 1988	Female rape victims	WL vs SIT vs supportive vs assertion training	All active treatments superior to PBO
Resick & Schnicke, 1992	19 rape victims	Combined vs WL	Combined superior to wait list
Foa et al., 1995	Women rape victims	E vs SIT vs combined	All 3 effective
Marks et al., 1998	87 civilian trauma victims	Relaxation vs SIT vs cognitive restructuring vs combination	All superior to relaxation

\*Combined = exposure + anxiety management techniques



# EYE MOVEMENT DESENSITIZATION AND REPROCESSING

<b>Study</b>	<b>Population</b>	<b>Comparison</b>	<b>Result</b>
Boudewyns et al., 1993	Veterans	EMDR vs E vs milieu	All negative
Pitman et al., 1996	17 Vietnam veterans	EMDR vs EMDR without eye movement	No difference between groups
Wilson et al., 1995	80 male & female trauma victims	EMDR vs delayed treatment	EMDR superior
Vaughan et al., 1994	36 male & female with PTSD	EMDR vs E vs muscle relaxation vs WL	All active treatments effective
Jensen et al., 1994	25 Vietnam veterans	EMDR vs milieu	No difference
Rothman, 1995	21 female victims	EMDR vs WL	EMDR superior


# EXPOSURE STUDIES

Study	Population	Comparison	Results
Brom et al., 1989	112 males & females	E* vs psychodynamic vs hypnosis vs WL*	All active treatments superior to waitlist
Cooper & Clum, 1987	26 Vietnam veterans	Standard treatment vs standard treatment + E	Exposure group increased improvement
Keane et al., 1989	24 Vietnam veterans	E vs WL	Exposure group more improved, especially re-experiences
Boudewyns et al., 1990	Vietnam veterans	E vs individual counseling	Exposure improved psychologically but not physiologically or PTSD symptoms
Foa et al., 1991	Women civilian trauma	Supportive vs E vs WL vs SIT*	SIT & exposure improved on all PTSD clusters

\*E = exposure-based treatment  
 WL = wait list control  
 SIT = stress inoculation training

# PTSD

## Treatment of PTSD by Exposure and/or Cognitive Restructuring



Marks I et al. *Arch Gen Psychiatry*. 1998;55:317–325.

# PHARMACOTHERAPY

**Neurobiological basis**

**Evidence of efficacy**

**What responds**

5. PTSD
6. related pathology

**Who responds**

5. Type of trauma
6. comorbidity
7. gender
8. culture

# **AIMS OF PHARMACOTHERAPY**

**Reduce core symptoms**

**Reduce associated symptoms**

**Facilitate other therapy**

# RELEVANCE OF INDOLAMINES TO PTSD

**Animal models**

**5. conditioned avoidance, stress resilience**

**mCPP effects**

**Reduced MAO activity**

**Paroxetine binding**

**Symptoms of PTSD**

# PLACEBO-CONTROLLED TRIALS

Study	Drug	N	Population	Results
Davidson et al.	Amitriptyline	62	Combat	Superior to PBO
Kosten et al.	Imipramine Phenelzine	61	Combat	Both superior to PBO
Katz et al.	Brofaromine	45	Mixed	Superior to PBO
Baker et al.	Brofaromine	113	Mixed	Superior to PBO
van der Kolk	Fluoxetine	47	Mixed	Superior to PBO in civilians only
Davidson et al.	Fluoxetine	64	Civilian	Superior to PBO
Davidson et al.	Sertraline	109	Civilian	Superior to PBO
Brady et al.	Sertraline	187	Civilian	Superior to PBO

## *PTSD*

# Medications Studied

---

**5. Benzodiazepines**

**6. Antidepressants**

- TCAs
- MAOIs
- SSRIs
- 5-HT<sub>2</sub> antagonists

**7. Anticonvulsants**

**8. Noradrenergic agents: clonidine, propranolol**




# **TYPE OF TRAUMA AND RESPONSE TO TREATMENT**

# BROFAROMINE SAMPLE

<b>Sample</b>	<b>N = 182</b>
<b>Sites</b>	<b>USA, England, Ireland, France, Norway</b>
<b>Duration of Treatment</b>	<b>12-14 weeks</b>
<b>Men:Women</b>	<b>74:26</b>
<b>Age (years)</b>	<b>41.9</b>

# BEREAVEMENT-RELATED PTSD



# DIFFERENCES IN BEREAVEMENT-RELATED PTSD vs NON-BEREAVEMENT RELATED PTSD

**Demographic**

Older, Male

**Trauma**

Earlier; more; longer-lasting PTSD

**Symptoms**

Less intrusive

Less startle

More


hypervigilance anhedonia/numbing

**Treatment**


Poorer overall response

# OVERALL RESPONSE RATES


## Brofaromine and Placebo




# RESPONSE TO TREATMENT IN DIFFERENT COUNTRIES



# SEXUAL TRAUMA-RELATED PTSD




# DOES COMORBID PERSONALITY DISORDER AFFECT THE RESPONSE TO AN SSRI?






# DOES COMORBID DEPRESSION AFFECT THE RESPONSE TO AN SSRI?




# PTSD Treatment With SSRIs

## Open-Label Sertraline in Comorbid PTSD and Alcoholism



Brady KT et al. *J Clin Psychiatry*. 1995;56:502–505.

# RESPONSE TO SERTRALINE IN 19 COMBAT VETERANS WITH PTSD AND MDD



**N=19**

**At least 12 weeks  
of treatment**

**Failure of other  
antidepressants**


**(N=12)**

**(N=7)**

## PTSD

# Treatment With Benzodiazepines

### Effect of Alprazolam



Braun P et al. *J Clin Psychiatry*. 1990;51:236–238.

# **ADVANTAGES AND DISADVANTAGES OF TCAs**

## **Advantages**

**Effective in PTSD**

**Abuse-free**

**Once daily**

**Hypnotic effects**

## **Disadvantages**

**Numerous side effects**

**Poorly tolerated**


**Dangerous in overdose**

**Wide dose range**

# PTSD

## Treatment With Tricyclics

### Studies Comparing Amitriptyline and Imipramine With Placebo



Davidson J et al. *Arch Gen Psychiatry* 1990;47:259-266.  
Kosten TR et al. *J Nerv Ment Dis*. 1991;179:366-370.

# ADVANTAGES AND DISADVANTAGES OF MAOIs

## Advantages

Effective in PTSD

May be particularly useful in complex cases

## Disadvantages

Numerous side effects

Poor tolerance


Dietary & other restrictions

Dangerous in overdose

# PTSD

## Treatment With MAOIs

### Studies Comparing Phenelzine and Brofaromine With Placebo



Kosten TR et al.  
*J Nerv Ment Dis.*  
1991;179:366-370.

Baker DG et al.  
*Psychopharmacology*  
. 1995;122:386-389.

Katz RJ et al.  
*Anxiety.*  
1994-95;1:169-174.



# **ADVANTAGES AND DISADVANTAGES OF SSRIs**

## **Advantages**

**Effective on all  
PTSD symptoms**

**Abuse-free**

**Once daily**

## **Disadvantages**


**Medication interactions**

**GI, sexual, activating  
side effects**

**May be ineffective in  
some types of PTSD**


# GLOBAL SEVERITY OF PTSD

## Fluoxetine vs Placebo



# PTSD Treatment With SSRIs


## Effect of Fluoxetine




van der Kolk BA, Fislser RE. *Prim Care*. 1993;20:417-432.

# PTSD Treatment With SSRIs


## Effect of Fluoxetine in Symptom Clusters




# WHICH SYMPTOMS RESPOND TO AN SSRI?




# EFFECT OF FLUOXETINE ON QUALITY OF LIFE (SF36) IN PTSD: Pre- to Post-Treatment



# IMPROVEMENT IN DISABILITY: Fluoxetine vs Placebo



# IMPROVEMENT IN STRESS VULNERABILITY: Fluoxetine vs Placebo





# SEQUENCE OF SYMPTOM IMPROVEMENT WITH FLUOXETINE (DTS)

	Week					
	2	4	6	8	10	12
Hypervigilance	**	***	***	*	**	***
Poor concentration	**	***	***	*	***	**
Upset by reminders	*	*			*	*
Estrangement		**	**	*	**	**
Anhedonia					*	**
Avoid thoughts				*		*
Foreshortened future						*

\*p<0.05


\*\*p<0.01

\*\*\*p<0.001

# SEQUENCE OF SYMPTOM IMPROVEMENT WITH FLUOXETINE (SIP)


	Week		
	4	8	12
Startle	**	*	**
Concentration	**		**
Intrusive recollections	**		**
Physiological symptoms		**	**
Estrangement			*
Numbing			*
	*p<0.05		*p<0.01

# Sertraline vs Placebo in Non-Combat-related PTSD



Brady et al.. JAMA 2000, in press


# RESPONSE TO SERTRALINE IN 5 RAPE VICTIMS WITH PTSD



*Rothbaum et al. J Trauma Stress 1996;9:865-871*

# Paroxetine in PTSD

## Efficacy of paroxetine in non-combat-related PTSD



Marshall et al, 1998

# PTSD

## Treatment With Nefazodone

### Open-Label Clinical Trials


Investigator	Population	N	Duration (Weeks)	Mean Endpoint (mg/day)
Weisler, Davidson et al	Multiple etiology	386	17	12
Hertzberg et al	Combat	10	12	490
Mellman et al	Combat, Holocaust	11	6	272
Petty et al	Combat, Sexual trauma	36	8	583
Tucker et al	Multiple etiology	10	10	*
Zisook et al	Combat	21	12	400
<b>Overall</b>	<b>Mixed trauma (23% females, 77% male)</b>	<b>105</b>	<b>6–12</b>	<b>272–583</b>

\*Dosage range 100–600 mg/day.

Hidalgo R. Int Clin Psychopharmacol. 1999;14:61–68.

## PTSD

# Open-Label Treatment With Nefazodone Efficacy (% Responders) Based on PTSD Main Scales\*




Sites: 1: Petty et al, Dallas VAMC; 2: Mellman et al, Miami VAMC (1997);  
3: Zisook et al, San Diego VAMC (1998); 4: Hertzberg et al, Durham VAMC (1998);  
5: Davidson et al, DUMC and Raleigh (1998); 6: Tucker et al, Oklahoma University (1998).

\*Responder is defined as decrease  $\geq 30\%$  from baseline.

Hidalgo R. *Int Clin Psychopharmacol*. 1999;14:61–68.


## PTSD

# Mean Percentage Change In Individual Symptoms After Treatment With Nefazodone





# COMBAT-RELATED PTSD RESPONDS TO TCA & MAOI, BUT NOT SSRI



# *PTSD*

## **Summary**

---

- 5. PTSD is common**
  - Usually chronic
  - Presentations vary
  - Comorbidity is the rule
- 6. Comprehensive assessment of patients is critical to develop an individualized treatment plan**
- 7. Treatment often involves multiple modalities**

# CONCLUSIONS

PTSD prevalent and *treatable* disorder

CBT effective


Antidepressant agents effective

5. SSRI, MAOI, TCA, RIMA

Combined CBT & pharmacotherapy  
trial needed

# Lifetime Prevalence of PTSD

---




Breslau et al. *Arch Gen Psychiatry*. 1991;48:216-222.

Kessler et al. *Arch Gen Psychiatry*. 1995;52:1048-1060.

# Comorbidity in PTSD


## *National Comorbidity Study*

MEN




- 1 Other Diagnoses
- 2 Other Diagnoses
- 3 Other Diagnoses
- No Other Diagnosis

WOMEN



- 1 Other Diagnoses
- 2 Other Diagnoses
- 3 Other Diagnoses
- No Other Diagnosis


# Lifetime History of Suicidal Attempts by Anxiety Disorder



General US population lifetime rates of suicide attempts range from 2.9% to 4.6%.


Kessler RC, *Archives of General Psychiatry*. 1999; Moscicki EK, *Yale Journal of Biology and Medicine*. 1988

# Disability Weights (Rating Scale)



# PTSD: Unmet Medical Need

Few Are Treated



% untreated

50%

90%

75%

80%

50%

30%



# PTSD Treatment Options



**Psychosocial**  
Exposure therapy  
Cognitive therapy  
Anxiety management  
Desensitization  
EMDR  
Hypnotherapy

**Pharmacologic**  
TCAs  
MAOIs  
*SSRIs*  
Mood stabilizers  
Antianxiety agents

EMDR = eye movement desensitization and reprocessing.

# Post Lecture Exam

## Question 1

True or False:

1. The prevalence of PTSD is higher in women than men.

## Question 2

True or False:

2. Combat-related PTSD is not responsive to treatment.

## Question 3

True or False:

- Propranolol is an effective treatment for PTSD.

## Question 4

1. Pharmacological agents with proven efficacy in PTSD include all but which of the following:
  - A. SSRI's
  - B. TCA's
  - C. MAOI's
  - D. Benzodiazepines
  - E. Anticonvulsants

## Question 5

1. The psychosocial PTSD treatment with the strongest evidence for efficacy is:
  - A. EDMR
  - B. CBT
  - C. Breathing relaxation
  - D. Exposure
  - E. Thought-stopping

# Answers to Pre & Post Competency Exams

1. True
2. False
3. False
4. D
5. D